Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

285 Stories from Volunteers, Donors & Supporters

4

General Member of the Public

Rating: 5

The resurgence of psychedelic and empathogenic research in the 21st Century is due, almost entirely, to Rick Doblin and MAPS. With the number of our military personal suffering from PTSD skyrocketing, their research will mean the difference between a full and fulfilling life and one of misery for tens of thousands of our troops.

Review from Guidestar

3

General Member of the Public

Rating: 5

Wonderful organization!!! Professional, passionate, and hard working individuals determined to assist humanity in recognizing the intrinsic and medical value of previously demonized chemicals and plants.

Review from Guidestar

9

General Member of the Public

Rating: 5

MAPS is the only professional scientific organisation which explores the possibilities of psychedelic drugs in psychotherapy - regarding the sorrow that could be relieved using MDMA and other drugs, MAPS' work is most important.

Review from Guidestar

3

General Member of the Public

Rating: 5

MAPS has always provided me with accurate information about psychedelics and the past and present research regarding them - and so much more! I cannot thank the organization enough for what they have done and the work in which they are presently involved. Their up-hill battle for the proper treatment of and with psychedelics is truly heroic! The conference in San Jose was an excellent product of their hard work and I greatly appreciated the opportunity to meet with so many like-minded individuals for the chance to educate each other with the knowledge we have been striving so hard to attain and spread. THANK YOU.

Review from Guidestar

3

General Member of the Public

Rating: 5

MAPS is a fantastic organization filling a very necessary role. An entire untapped power potentially lies in psychedelics and MAPS is THE foremost scientific venture into their world.

3

General Member of the Public

Rating: 5

As a health care professional, I honor the invaluable contribution that MAPS makes to the world of science and medicine.

3

General Member of the Public

Rating: 5

MAPS is an association which study the therapeutic benefits of psychedelics. I found psychedelics beneficial and wanted to learn more so went searching and found MAPS. They are a source of balanced scientific research and what I believe needs to continue in a field of such great potential.

3

General Member of the Public

Rating: 5

MAPS provided a forum for people from many diverse communities to converge with their new research results, discoveries and ideas. Now that the FDA approved research using various psychedelic substances, huge amounts of information is beginning to emerge. Promising results have been proven, providing hope for people who suffer from P.T.S.D., cluster headaches, end of life anxiety and many other problems. Public education in these fields is important. Additionally there have been breakthroughs in consciousness that were demonstrated at this conference. The visionary art was my favorite part, though, and discovering Randall Fontes and his Light Mandala there has made a big difference in my life's journey. It was MAPS that made this possible.

8

General Member of the Public

Rating: 5

Illegal Drugs. We've been led to believe we should all "Just Say No" to them because there's nothing redeeming about them. We should pay billions of dollars each year fighting a war against U.S. citizens. We should lock our neighbors in jail cells for using substances safer than alcohol. We should live in ignorance of things that could potentially help us, all the while knowing there are many legal substances being used that cause much more harm. MAPS says that certain illegal drugs DO have the potential to help people heal. Mentally, physically and in many cases spiritually. They just want permission from the government to legally prove this in a scientific manner. The majority of the public unfortunately has a negative perception of marijuana, lsd, "magic mushrooms" and ecstacy. But MAPS knows each of these can and has been helpful in treating many things including PTSD. I commend MAPS for the work they're doing and I'm excited by the thought of how many people they're going to help with their research.

9

General Member of the Public

Rating: 5

This organisation is the leading group in understanding the significant link between psychedelic drugs and many psychotherapeutic methods. They are constantly trying new techniques in the way of helping troubled patients or even in some cases patients with a serious illness such as those sufferring from cluster headaches. This area of research is left untouched by government studies and one of the only ways psychotherapists can utilise such tools is through the groundbreaking work of this charity.